Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Li-Na He"'
Autor:
Li-Na He, Haifeng Li, Wei Du, Sha Fu, Linfeng luo, Tao Chen, Xuanye Zhang, Chen Chen, Yongluo Jiang, Yixing Wang, Yuhong Wang, Hui Yu, Yixin Zhou, Zuan Lin, Yuanyuan Zhao, Yan Huang, Hongyun Zhao, Wenfeng Fang, Yunpeng Yang, Li Zhang, Shaodong Hong
Publikováno v:
iScience, Vol 26, Iss 7, Pp 107058- (2023)
Summary: The immune and stromal contexture within the tumor microenvironment (TME) interact with cancer cells and jointly determine disease process and therapeutic response. We aimed at developing a risk scoring model based on TME-related genes of sq
Externí odkaz:
https://doaj.org/article/9435e0cd9f3d4bc2850761808524bced
Autor:
Linfeng Luo, Anlin Li, Sha Fu, Wei Du, Li-Na He, Xuanye Zhang, Yixing Wang, Yixin Zhou, Yang Yunpeng, Zhang Li, Shaodong Hong
Publikováno v:
Immunologic Research. 71:213-228
Non-small-cell lung cancer (NSCLC) remains the major cause of cancer-related death. Immune checkpoint inhibition has become the cornerstone treatment for NSCLC. Cuproptosis is a newly identified form of cell death relying on mitochondrial respiration
Autor:
Wen-Fei Wei, Chen-Fei Zhou, Xiang-Guang Wu, Li-Na He, Lan-Fang Wu, Xiao-Jing Chen, Rui-Ming Yan, Mei Zhong, Yan-Hong Yu, Li Liang, Wei Wang
Publikováno v:
Cell Death & Disease. 13
Autor:
Tao Chen, Li-na He, Chen Chen, Yixin Zhou, Zuan Lin, Haifeng Li, Shaodong Hong, Xuanye Zhang, Li Zhang, Yuhong Wang
Publikováno v:
Cancer Immunology, Immunotherapy. 71:1247-1255
The use of anti-programmed cell death-1 (PD-1) antibodies in treating malignancies is increasing; however, most registered clinical trials on anti-PD-1 antibodies exclude patients infected with hepatitis B virus (HBV). This retrospective study aimed
Autor:
Chen Chen, Bei Zhang, Yixin Zhou, Hui Yu, Shaodong Hong, Xuanye Zhang, Ping Chen, Xiuyu Cai, Li-na He
Publikováno v:
Cancer Immunology, Immunotherapy. 71:637-644
Programmed cell death-ligand 1 inhibitors plus chemotherapy (PD-L1 + Chemo) have achieved substantial progress in extensive-stage small-cell lung cancer (ES-SCLC). However, evidence about programmed cell death 1 inhibitors plus chemotherapy (PD-1 + C
Autor:
Xuanye Zhang, Yixin Zhou, Hualin Chen, Chen Chen, Zuan Lin, Li-na He, Wei Du, Tao Chen, Shaodong Hong, Sha Fu
Publikováno v:
Frontiers in immunology. 13
BackgroundPulmonary lymphoepithelioma-like carcinoma (PLELC) is a distinctive subtype of non-small cell lung carcinoma that was not well presented in clinical studies. The management of advanced PLELC remains an important, unmet need due to the pauci
Autor:
Xuanye Zhang, Liangping Xia, Bei Zhang, Ping Chen, Shaodong Hong, Li-na He, Chen Chen, Yixin Zhou, Hui Yu, Sha Fu
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 11 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 11 (2021)
Anti-PD-1)/programmed cell death-ligand 1 (PD-L1) antibody plus platinum-based chemotherapy (PBC) has replaced PBC as first-line treatment for patients with non-squamous (sq) non-small cell lung cancer (NSCLC) lacking targetable driver mutations. How
Autor:
Chen Chen, Yixin Zhou, Xuanye Zhang, Yuhong Wang, Li-na He, Zuan Lin, Tao Chen, Yongluo Jiang, Shaodong Hong, Li Zhang
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunology
Frontiers in Immunology
BackgroundMore and more immune-oncology trials have been conducted for treating various cancers, yet it is unclear what the reporting quality of immune-oncology trials is,and characteristics associated with higher reporting quality.ObjectiveThis stud
Autor:
Zuan Lin, Xuanye Zhang, Yixin Zhou, Chen Chen, Li-na He, Haifeng Li, Yuhong Wang, Tao Chen, Shaodong Hong, Li Zhang
Publikováno v:
Cancer Immunology, Immunotherapy. 71:1257-1257
Autor:
Chen-Fei Zhou, Mei Zhong, Xiang-Guang Wu, Xiao-Jing Chen, Li Liang, Yanhong Yu, Wen-Fei Wei, Lan-Fang Wu, Wei Wang, Li-Na He, Rui-Ming Yan
Publikováno v:
Cell Death & Disease
Cell Death and Disease, Vol 8, Iss 12, Pp 1-13 (2017)
Cell Death and Disease, Vol 8, Iss 12, Pp 1-13 (2017)
MicroRNAs have implicated in the relapse and metastasis of cervical cancer, which is the leading cause of cervical cancer-related mortality. However, the underlying molecular mechanisms need further elucidation. Our present study revealed that miR-22